41
Participants
Start Date
October 31, 2004
Primary Completion Date
November 30, 2007
Study Completion Date
March 31, 2008
CHR-2797 (tosedostat)
Drug was given orally, once daily, ensuring a dosing interval of approximately 24 hours. Dose escalations took place starting at 10mg and escalating (per protocol) as follows: 20, 40, 90, 130, 180, 240 and 320 mg
Lead Sponsor
Institute of Cancer Research, United Kingdom
OTHER
Chroma Therapeutics
INDUSTRY